10X Genomics (TXG) Stock Price

10X Genomics Price

NASDAQ·CLOSED
45.60USD-2.03 (-4.37 %)
Market closed

Over the last 8 years 10X Genomics grew revenue by 31.9% annually, reaching 642.82 M USD. For 10X Genomics, the net margin of -6.8% is up versus -11.9% a few years ago. The consensus 12-month price target for 10X Genomics is 18.36 USD, about 59.7% below where the stock trades today. Of 21 analysts, 7 rate the stock a buy — an overall Hold consensus. The stock trades about 302% above its 52-week low.

10X Genomics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of 10X Genomics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how 10X Genomics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing 10X Genomics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

10X Genomics Stock Price History
Date10X Genomics Price
8/6/202645.60 USD
8/5/202647.63 USD
8/4/202646.28 USD
8/3/202647.01 USD
7/31/202647.27 USD
7/30/202649.43 USD
7/29/202646.28 USD
7/27/202645.60 USD
7/23/202648.06 USD
7/22/202647.05 USD
7/21/202647.20 USD
7/20/202643.22 USD
7/17/202643.74 USD
7/16/202644.48 USD
7/15/202645.75 USD
7/14/202645.79 USD
7/13/202642.56 USD
7/10/202642.73 USD
7/9/202643.10 USD
7/8/202636.31 USD
7/7/202637.83 USD
7/6/202639.65 USD
7/2/202639.01 USD
7/1/202639.05 USD
6/30/202638.34 USD
6/29/202636.83 USD
6/26/202636.75 USD
6/25/202635.73 USD
6/24/202634.60 USD
6/23/202631.87 USD
6/22/202635.10 USD
6/18/202635.24 USD
6/17/202633.31 USD
6/16/202632.91 USD
6/15/202631.75 USD
6/12/202628.96 USD
6/11/202629.46 USD
6/10/202630.99 USD
6/9/202630.59 USD
6/8/202629.18 USD
6/5/202631.43 USD
6/4/202634.90 USD
6/3/202631.58 USD
6/2/202629.67 USD
6/1/202628.57 USD
5/29/202628.23 USD
5/28/202627.40 USD
5/27/202624.12 USD
5/26/202624.52 USD
5/22/202624.26 USD
5/21/202624.69 USD
5/20/202623.05 USD
5/19/202622.29 USD
5/18/202621.45 USD
5/15/202621.20 USD
5/14/202621.52 USD
5/13/202621.07 USD
5/12/202620.92 USD
5/11/202620.50 USD
5/8/202621.60 USD
5/7/202622.42 USD
5/6/202622.74 USD
5/5/202622.01 USD
5/4/202621.65 USD
5/1/202622.43 USD
4/30/202622.05 USD
4/29/202620.20 USD
4/28/202621.37 USD
4/27/202622.28 USD
4/24/202622.08 USD
4/22/202622.83 USD
4/21/202622.97 USD
4/20/202624.59 USD
4/17/202626.08 USD
4/16/202625.24 USD
4/15/202625.35 USD
4/14/202624.80 USD
4/13/202623.58 USD
4/10/202623.27 USD
4/9/202623.00 USD
4/8/202623.02 USD
4/7/202621.82 USD
4/6/202621.89 USD
4/2/202622.33 USD
4/1/202622.05 USD
3/31/202621.23 USD
3/30/202619.81 USD
3/27/202619.48 USD
3/26/202620.43 USD
3/25/202620.91 USD
3/24/202619.81 USD
3/23/202619.14 USD
3/20/202618.39 USD
3/19/202618.38 USD
3/18/202617.35 USD
3/17/202618.09 USD
3/16/202616.69 USD
3/13/202618.79 USD
3/12/202618.94 USD
3/11/202620.46 USD
3/10/202620.46 USD
3/9/202620.91 USD
3/6/202620.81 USD
3/5/202621.64 USD
3/4/202622.37 USD
3/3/202622.62 USD
3/2/202623.14 USD
2/27/202623.05 USD
2/26/202622.13 USD
2/25/202619.66 USD
2/24/202619.10 USD
2/23/202618.89 USD
2/20/202618.88 USD
2/19/202619.19 USD
2/18/202619.57 USD
2/17/202618.62 USD
2/13/202618.12 USD
2/12/202617.51 USD
2/11/202619.15 USD
2/10/202619.15 USD
2/9/202618.54 USD
2/6/202618.61 USD
2/5/202617.70 USD
2/4/202619.06 USD
2/3/202619.28 USD
2/2/202619.95 USD
1/30/202620.20 USD
1/29/202620.80 USD
1/28/202621.08 USD
1/27/202621.62 USD
1/26/202622.50 USD
1/23/202622.38 USD
1/22/202623.19 USD
1/21/202622.68 USD
1/20/202622.05 USD
1/16/202620.52 USD
1/15/202621.20 USD
1/14/202620.92 USD
1/13/202620.52 USD
1/12/202619.80 USD
1/9/202620.46 USD
1/8/202619.29 USD
1/7/202619.99 USD
1/6/202619.31 USD
1/5/202618.32 USD
1/2/202616.62 USD
12/31/202516.31 USD
12/30/202516.29 USD
12/29/202516.15 USD
12/26/202516.49 USD
12/24/202516.69 USD
12/23/202516.50 USD
12/22/202516.94 USD
12/19/202516.05 USD
12/18/202516.00 USD
12/17/202515.75 USD
12/16/202515.71 USD
12/15/202515.76 USD
12/12/202515.46 USD
12/11/202516.54 USD
12/10/202517.53 USD
12/9/202517.84 USD
12/8/202517.47 USD
12/5/202517.77 USD
12/4/202518.15 USD
12/3/202517.87 USD
12/2/202517.94 USD
12/1/202518.08 USD
11/28/202518.81 USD
11/26/202518.75 USD
11/25/202519.07 USD
11/24/202520.13 USD
11/21/202518.34 USD
11/20/202516.46 USD
11/19/202515.65 USD
11/18/202515.56 USD
11/17/202515.70 USD
11/14/202515.89 USD
11/13/202516.35 USD
11/12/202516.69 USD
11/11/202516.59 USD
11/10/202517.08 USD
11/7/202515.25 USD
11/6/202513.00 USD
11/5/202513.49 USD
11/4/202513.36 USD
11/3/202513.70 USD
10/31/202513.64 USD
10/30/202512.44 USD
10/29/202512.90 USD
10/28/202513.34 USD
10/27/202513.59 USD
10/24/202513.77 USD
10/23/202513.36 USD
10/22/202512.26 USD
10/21/202513.03 USD
10/20/202513.14 USD
10/17/202511.83 USD
10/16/202512.38 USD
10/15/202511.89 USD
10/14/202511.54 USD
10/13/202511.60 USD
10/10/202511.47 USD
10/9/202511.71 USD
10/8/202512.07 USD
10/7/202511.60 USD
10/6/202512.64 USD
10/3/202512.75 USD
10/2/202512.31 USD
10/1/202512.39 USD
9/30/202511.69 USD
9/29/202511.34 USD
9/26/202511.72 USD
9/25/202511.95 USD
9/24/202512.06 USD
9/23/202512.49 USD
9/22/202513.04 USD
9/19/202513.04 USD
9/18/202513.27 USD
9/17/202512.86 USD
9/16/202513.13 USD
9/15/202513.35 USD
9/12/202512.64 USD
9/11/202513.06 USD
9/10/202512.59 USD
9/9/202513.50 USD
9/8/202513.93 USD
9/5/202513.96 USD
9/4/202513.57 USD
9/3/202513.34 USD
9/2/202513.37 USD
8/29/202514.01 USD
8/28/202514.28 USD
8/27/202514.02 USD
8/26/202514.03 USD
8/25/202514.07 USD
8/22/202514.30 USD
8/21/202513.10 USD
8/20/202513.36 USD
8/19/202513.41 USD
8/18/202513.46 USD
8/15/202513.36 USD
8/14/202513.24 USD
8/13/202513.57 USD
8/12/202512.81 USD
8/11/202512.31 USD
Access this data via the Eulerpool API
Get Free API Key

10X Genomics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
618.69 M USD
-265.33 M USD
-255.10 M USD
Jan 1, 2024
610.78 M USD
-194.56 M USD
-182.63 M USD
Jan 1, 2025
642.82 M USD
-110.89 M USD
-43.54 M USD
Jan 1, 2026 (e)
613.69 M USD
-144.28 M USD
-101.97 M USD
Jan 1, 2027 (e)
668.23 M USD
-157.10 M USD
-89.54 M USD
Jan 1, 2028 (e)
726.96 M USD
-170.91 M USD
-52.27 M USD
Jan 1, 2029 (e)
792.70 M USD
-186.36 M USD
-46.82 M USD
Jan 1, 2030 (e)
892.85 M USD
-209.91 M USD
-24.68 M USD

10X Genomics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 9:53 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e
71.00146.00245.00298.00490.00516.00618.00610.00642.00613.00668.00726.00792.00892.00
–105.6367.8121.6364.435.3119.77-1.295.25-4.528.978.689.0912.63
84.5180.1475.1080.5484.9076.7466.1867.8769.0069.0069.0069.0069.0069.00
60.00117.00184.00240.00416.00396.00409.00414.00443.00422.99460.94500.96546.50615.51
-18.00-109.00-30.00-85.00-53.00-167.00-265.00-194.00-110.00-144.00-157.00-170.00-186.00-209.00
-25.35-74.66-12.24-28.52-10.82-32.36-42.88-31.80-17.13-23.49-23.50-23.42-23.48-23.43
-18.00-112.00-31.00-542.00-58.00-166.00-255.00-182.00-43.00-101.00-89.00-52.00-46.00-24.00
–522.22-72.321,648.39-89.30186.2153.61-28.63-76.37134.88-11.88-41.57-11.54-47.83
12.0014.0096.03107.39111.90114.76118.57121.60127.08127.08127.08127.08127.08127.08
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales 10X Genomics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue 10X Genomics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare 10X Genomics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares 10X Genomics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against 10X Genomics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

10X Genomics stock margins

The 10X Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of 10X Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for 10X Genomics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
85.04 %
-10.84 %
-11.89 %
Jan 1, 2022
76.76 %
-32.55 %
-32.17 %
Jan 1, 2023
66.16 %
-42.89 %
-41.23 %
Jan 1, 2024
67.86 %
-31.85 %
-29.90 %
Jan 1, 2025
69.05 %
-17.25 %
-6.77 %
Jan 1, 2026 (e)
69.05 %
-23.51 %
-16.62 %
Jan 1, 2027 (e)
69.05 %
-23.51 %
-13.40 %
Jan 1, 2028 (e)
69.05 %
-23.51 %
-7.19 %

10X Genomics Stock Revenue, EBIT, Earnings per Share

The 10X Genomics earnings per share therefore indicates how much revenue 10X Genomics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
4.38 USD
-0.47 USD
-0.52 USD
Jan 1, 2022
4.50 USD
-1.46 USD
-1.45 USD
Jan 1, 2023
5.22 USD
-2.24 USD
-2.15 USD
Jan 1, 2024
5.02 USD
-1.60 USD
-1.50 USD
Jan 1, 2025
5.06 USD
-0.87 USD
-0.34 USD
Jan 1, 2026 (e)
4.85 USD
-1.14 USD
-0.81 USD
Jan 1, 2027 (e)
5.28 USD
-1.24 USD
-0.71 USD
Jan 1, 2028 (e)
5.74 USD
-1.34 USD
-0.41 USD

10X Genomics business model & stock analysis

10X Genomics is a US-based company specializing in the development of life science products. It was founded in 2012 by Serge Saxonov and Ben Hindson and is headquartered in Pleasanton, California. The company's business model focuses on providing technology platforms that enable researchers and scientists to analyze and understand complex biological data. It combines microfluidics, genomics, and bioinformatics. 10X Genomics is divided into different divisions, each focusing on different products and applications: Single-Cell Genomics, Long-Read Sequencing, Immune Profiling, and Spatial Transcriptomics. The company's products include the Chromium platform for cell type identification, disease research, and drug screening; Long-Read Sequencing technology for reading larger DNA fragments; tools and solutions for immune profiling and understanding the immune system; and Spatial Transcriptomics technology for studying the spatial organization of gene expression in tissues. 10X Genomics also offers other products and solutions in the field of genomic sequencing and analysis, including DNA preparation and sequencing kits, software for DNA data analysis and interpretation, and consulting and training services. The company has received various awards and recognition for its innovative approach, including the Innovation Award from The Scientist magazine and the Disruptive Technology Award from the Wall Street Journal. Overall, 10X Genomics has become a leading company in the life science industry, contributing to the advancement of scientific understanding and supporting progress in medicine and biotechnology.

10X Genomics SWOT Analysis

Strengths

1. Technological Innovation: 10X Genomics Inc is known for its cutting-edge technology in single-cell genomics. Their innovative solutions enable researchers to gain unprecedented insights into complex biological systems.

2. Broad Product Portfolio: The company offers a wide range of products and solutions, including instruments, consumables, and software, catering to various research needs in genomics and transcriptomics.

3. Strong Customer Base: 10X Genomics has established a strong customer base globally, including leading academic institutions and pharmaceutical companies, with high customer satisfaction and loyalty.

4. Strategic Partnerships: The company has forged strategic partnerships with key players in the genomics industry, enhancing its market presence, expanding distribution networks, and fostering collaborations.

Weaknesses

1. High Pricing: The advanced technologies offered by 10X Genomics come at a premium price, limiting accessibility for smaller research institutions or budget-constrained customers.

2. Dependence on Research Funding: The company's revenue is significantly dependent on research grants and funding, which are subject to fluctuations and uncertainties, impacting financial stability.

3. Limited Global Market Penetration: While the company has established a strong presence in certain regions, its market penetration in other geographical areas may be relatively low, indicating room for further growth.

Opportunities

1. Increasing Demand for Genomic Research: The growing interest in personalized medicine and the need for understanding complex diseases present tremendous opportunities for 10X Genomics to expand its customer base and market share.

2. Mergers & Acquisitions: The company can explore strategic acquisitions or partnerships to enhance its product offerings, access new technologies, and strengthen its competitive position in the genomics market.

3. Expansion into Emerging Markets: 10X Genomics can focus on expanding its operations into emerging markets where the adoption of genomics research is on the rise, opening up new revenue streams.

Threats

1. Intense Competition: The genomics industry is highly competitive, with several established players and new entrants competing for market share, posing a threat to 10X Genomics' growth and profitability.

2. Regulatory Challenges: Evolving regulations and compliance requirements in the genomics sector could increase operational complexities and costs for 10X Genomics, limiting its ability to address certain markets.

3. Technological Advancements by Competitors: The rapid pace of technological advancements by competitors may pose a threat to 10X Genomics' market position if it fails to innovate and stay at the forefront of new developments.

10X Genomics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

10X Genomics Employees
Details
Date
10X Genomics Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

10X Genomics Segments

10X Genomics Revenue by Segment (1/3)

  • 3 Years

  • 5 Years

  • Max

Consumables
Instruments
Instuments
Services
Service
Details
Date
Consumables
Instruments
Instuments
Services
Service
Jan 1, 2019
206.88 M USD
0.00 USD
34.95 M USD
0.00 USD
4.07 M USD
Jan 1, 2020
252.69 M USD
40.13 M USD
0.00 USD
6.03 M USD
0.00 USD
Jan 1, 2021
418.74 M USD
64.47 M USD
0.00 USD
7.28 M USD
0.00 USD
Jan 1, 2022
435.59 M USD
72.40 M USD
0.00 USD
8.43 M USD
0.00 USD
Jan 1, 2023
479.55 M USD
123.47 M USD
0.00 USD
15.70 M USD
0.00 USD
Jan 1, 2024
493.43 M USD
92.72 M USD
0.00 USD
24.64 M USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

10X Genomics Revenue by Segment (2/3)

  • Max

Products and services revenue
License and royalty revenue
Details
Date
Products and services revenue
License and royalty revenue
Jan 1, 2019
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
Jan 1, 2025
596.69 M USD
46.14 M USD

10X Genomics Revenue by Segment (3/3)

  • Max

Consumables
Instruments
Services
Details
Date
Consumables
Instruments
Services
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
507.18 M USD
56.78 M USD
32.73 M USD

10X Genomics Revenue by Region

  • 3 Years

  • 5 Years

  • Max

Americas
United States
Europe, Middle East and Africa
North America
Asia-Pacific
China
EMEA
Asia-Pacific (excluding China)
Asia Pacific
North America (excluding United States)
Details
Date
Americas
United States
Europe, Middle East and Africa
North America
Asia-Pacific
China
EMEA
Asia-Pacific (excluding China)
Asia Pacific
North America (excluding United States)
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
139.76 M USD
0.00 USD
29.92 M USD
58.00 M USD
0.00 USD
18.21 M USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
73.27 M USD
159.33 M USD
24.51 M USD
41.74 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
258.27 M USD
108.49 M USD
0.00 USD
0.00 USD
74.92 M USD
0.00 USD
42.09 M USD
0.00 USD
6.71 M USD
Jan 1, 2022
0.00 USD
284.99 M USD
117.07 M USD
0.00 USD
0.00 USD
59.56 M USD
0.00 USD
46.00 M USD
0.00 USD
8.79 M USD
Jan 1, 2023
373.19 M USD
0.00 USD
142.28 M USD
0.00 USD
103.26 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
347.77 M USD
0.00 USD
159.76 M USD
0.00 USD
103.26 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
358.77 M USD
0.00 USD
161.72 M USD
0.00 USD
122.33 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

10X Genomics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

10X Genomics historical P/E ratio, EBIT multiple, and P/S ratio

10X Genomics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

10X Genomics shares outstanding

The number of shares of 10X Genomics was 127.08 M in 2025. This indicates how many shares 10X Genomics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
111.90 M Stocks
Jan 1, 2022
114.76 M Stocks
Jan 1, 2023
118.57 M Stocks
Jan 1, 2024
121.60 M Stocks
Jan 1, 2025
127.08 M Stocks
Jan 1, 2026 (e)
127.08 M Stocks
Jan 1, 2027 (e)
127.08 M Stocks
Jan 1, 2028 (e)
127.08 M Stocks

Current 10X Genomics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
33.33 % (7)
Hold
66.67 % (14)
Sell
0.00 % (0)
12M Price Target
18.36
Last Price
52.03
Currency
USD
12M Return Potential
-64.71 %
LTM Return
0 %

10X Genomics Analyst Rating Actions

DateFirmActionRatingReliability
7/17/2026
Leerink Partners
Leerink Partners
MaintainedMarket Perform–
7/14/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
7/9/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
7/8/2026
Citigroup
Citigroup
MaintainedNeutral48
7/1/2026
Piper Sandler
Piper Sandler
MaintainedNeutral51
6/24/2026
Barclays
Barclays
MaintainedOverweight33
5/12/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
5/12/2026
JP Morgan
JP Morgan
MaintainedNeutral80
4/20/2026
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
4/20/2026
B of A Securities
B of A Securities
MaintainedNeutral70

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

10X Genomics Earnings Calls

2025

10X Genomics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/6/2026-0.25USD-148.00 MUSD-2026 Q2
5/7/2026-0.30USD-147.98 MUSD-2026 Q1
2/12/2026-0.21USD-160.22 MUSD-2025 Q4
8/7/2025-0.38USD-140.81 MUSD-2025 Q2
5/1/2024-0.46USD-161.88 MUSD-2024 Q1
2/13/2024-0.38USD-182.76 MUSD-2023 Q4
8/7/2023-0.33USD-149.01 MUSD-2023 Q2
5/2/2023-0.35USD-139.57 MUSD-2023 Q1
2/14/2023-0.32USD-150.53 MUSD-2022 Q4
11/2/2022-0.47USD-131.52 MUSD-2022 Q3

EESG©

Eulerpool ESG Scorecard© for the 10X Genomics stock

28/100
32
Environment
19
Social
33
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

10X Genomics shareholder structure

% Name
14.01894%
FMR LLC
FMR LLC
9.25904%
ARK INVESTMENT MANAGEMENT LLC
ARK INVESTMENT MANAGEMENT LLC
7.96516%
BLACKROCK, INC.
BLACKROCK, INC.
5.46261%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
4.27638%
QUANTINNO CAPITAL MANAGEMENT LP
QUANTINNO CAPITAL MANAGEMENT LP
4.16403%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
...

10X Genomics Beneficial Ownership Filings (SEC 13D/G)

Free Float
90.4%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
29.30%
Michael Robert Steed
Michael Robert Steed
SEC ↗
25.90%
Foresite Capital Management I, LLC (“FCM I”)
Foresite Capital Management I, LLC (“FCM I”)
SEC ↗
25.90%
Foresite Capital Fund II, L.P. (“FCF II”)
Foresite Capital Fund II, L.P. (“FCF II”)
SEC ↗
24.60%
James Tananbaum (“Tananbaum”)
James Tananbaum (“Tananbaum”)
SEC ↗
24.60%
Foresite Capital Management II, LLC (“FCM II”)
Foresite Capital Management II, LLC (“FCM II”)
SEC ↗
23.80%
Paladin Capital Management, LLC
Paladin Capital Management, LLC
SEC ↗
15.60%
FMR LLC
FMR LLC
SEC ↗
15.50%
Page 3 of 9 Pages
Page 3 of 9 Pages
SEC ↗
15.50%
Page 2 of 9 Pages
Page 2 of 9 Pages
SEC ↗
11.00%
Baillie Gifford & Co (Scottish partnership)
Baillie Gifford & Co (Scottish partnership)
SEC ↗

10X Genomics Executives and Management Board

10 members · avg. age 55 · 30 % women

SS

Mr. Serge Saxonov (48)

Chief Executive Officer, Co-Founder, Director · since 2012

7.93 M USD

Management

EW

Mr. Eric Whitaker (58)

Chief Legal Officer

7.00 M USD
BH

Dr. Benjamin Hindson (50)

President, Co-Founder, Chief Scientific Officer, Director · since 2012

4.27 M USD
AT

Mr. Adam Taich (50)

Chief Financial Officer

3.30 M USD

Board of Directors

AM

Mr. Alan Mateo (63)

Independent Director

477,994.00 USD
ST

Dr. Sarah Teichmann (49)

Independent Director

469,852.00 USD
JS

Dr. John Stuelpnagel (67)

Independent Chairman of the Board

318,302.00 USD
SK

Mr. Sridhar Kosaraju (47)

Independent Director

263,458.00 USD
KP

Ms. Kimberly Popovits (66)

Independent Director

258,052.00 USD
SS

Dr. Shehnaaz Suliman (53)

Independent Director

251,755.00 USD

Frequently asked questions about 10X Genomics

The business model of 10X Genomics Inc is focused on providing innovative solutions for single-cell genomics analysis. They develop and manufacture advanced instruments, software, and reagents that enable researchers to profile individual cells at high resolution. By offering comprehensive tools for single-cell analysis, 10X Genomics aims to revolutionize how scientists understand cellular diversity, gene expression, and the mechanisms underlying diseases. Through their state-of-the-art technologies, 10X Genomics empowers researchers across various disciplines to gain valuable insights into complex biological systems and ultimately accelerate discoveries in genomics research.

10X Genomics Inc is primarily active in the life sciences industry.

The main competitors of 10X Genomics Inc in the market include other innovative biotechnology companies such as Illumina, Pacific Biosciences, and Bio-Rad Laboratories.

10X Genomics Inc is a biotechnology company headquartered in Pleasanton, California. It was founded in 2012 by Serge Saxonov, Benjamin Hindson, and Kevin Ness with a vision to revolutionize genomics research. The company develops and commercializes innovative solutions that enable scientists to study genetic information at unprecedented resolution and scale. By employing its patented technology, 10X Genomics has empowered researchers across multiple disciplines to make groundbreaking discoveries in areas such as cancer research, drug discovery, and immunology. With a strong focus on innovation, 10X Genomics continues to shape the future of genomics research, ensuring its position as a leading player in the field.

10X Genomics Inc has achieved several significant milestones in its development. The company successfully launched its groundbreaking Chromium System, a single-cell analysis platform that enables researchers to analyze cellular heterogeneity at unprecedented resolution. This technological breakthrough has revolutionized genomics research and allowed scientists to gain invaluable insights into complex biological systems. Additionally, 10X Genomics Inc has made remarkable strides in expanding its product portfolio, continuously introducing innovative solutions that empower researchers with cutting-edge genomic tools. Furthermore, the company has established strong partnerships and collaborations with leading academic institutions and pharmaceutical companies, further validating 10X Genomics Inc's expertise and impact in the genomics field.

10X Genomics Inc is primarily present in the United States.

10X Genomics Inc represents a commitment to advancing scientific research and discovery. Their corporate philosophy emphasizes innovation, collaboration, and integrity. The company aims to empower researchers with cutting-edge tools and technologies to unlock new insights in genomics. By offering solutions that enable single-cell and spatial genomics analysis, 10X Genomics Inc plays a vital role in accelerating knowledge in biology and medicine. Their dedication to quality and customer satisfaction has established them as a leader in the field, making 10X Genomics Inc a trusted name in genomics research and a driving force for scientific progress.

Analysts currently set an average price target of 18.43 USD for the 10X Genomics stock (median: 18.36 USD), implying -64.6 % versus the latest price. The consensus is based on 21 analyst ratings.

10X Genomics Analyst Price Targets 2026

21 analysts currently rate the 10X Genomics stock: 7 recommend buying, 14 holding and 0 selling. For 2026, analysts expect 10X Genomics to generate revenue of 613.69 M USD and earnings per share of -0.80 USD.

10X Genomics Analyst Price Targets 2026

Converted at the current exchange rate, the 10X Genomics share trades at 39.49 EUR (45.60 USD).

The 10X Genomics share (TXG) is listed on 5 stock exchanges, including: NASDAQ (TXG), Frankfurt (1KJ.F), München (1KJ.MU), Düsseldorf (1KJ.DU), London (0A88.L).

The company 10X Genomics Inc. is a leading provider of genomics technologies and solutions. Its business model is focused on providing innovative tools and products to scientists, researchers, and other customers to improve the understanding of cell biology and genomics. 10X Genomics' main division is the production of single-cell genomics products. The company has developed a unique platform that allows researchers to study individual cells and collect genetic information from them. This platform offers higher resolution than previous technologies that relied on samples from multiple cells, which obscured the misunderstood heterogeneity of cell populations. Numerous differences occurring in cells can be uncovered, allowing scientists to gain new insights into biological processes. 10X Genomics also offers solutions for genome sequencing and has developed a revolutionary technology called Linked-Reads. With this technology, researchers can sequence regions of the genome that were previously inaccessible, leading to important discoveries. Linking specific regions in the DNA helps researchers study large genomic areas more quickly and identify complex structures such as chromosomal variations or gene fusion events. Additionally, 10X Genomics has a growing presence in the market for clinical applications of genomics technologies. The company is currently collaborating with several partners to develop tests and diagnostic tools for early cancer detection, among other future uses. 10X Genomics' business model is based on the development and manufacture of innovative products and technologies, as well as collaboration with customers to create tailored solutions and sell them with added value. The company has experienced rapid growth in the past and values continuous improvement and development of its products and services. In the future, 10X Genomics plans to continue working on new technologies and solutions while expanding and strengthening its existing customer base by closely collaborating with customers in research and clinical diagnostics. The company is demonstrating to the industry how analyzing individual cells in genomics can enable scientists to explore biological complexity in new, deeper ways.

The expected revenue of 10X Genomics is 613.69 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of 10X Genomics is -101.97 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of 10X Genomics is currently -56.83. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the 10X Genomics stock.

The price-to-sales ratio (P/S) of 10X Genomics is currently 9.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the 10X Genomics stock.

The Eulerpool Quality Score for 10X Genomics is 3/10.

The ISIN of 10X Genomics is US88025U1097. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of 10X Genomics is A2PPQJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of 10X Genomics is TXG. The ticker symbol is used to trade 10X Genomics shares on the stock exchange.

10X Genomics paid dividends every year for the past 0 years.

10X Genomics is assigned to the 'Health' sector.

The dividends of 10X Genomics are distributed in USD.

All fundamentals and in-depth analysis of 10X Genomics

Our stock analysis for 10X Genomics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 10X Genomics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

10X Genomics Stock
10X Genomics Revenue→
10X Genomics Stock
10X Genomics Net Income→
10X Genomics Stock
10X Genomics P/E→
10X Genomics Stock
10X Genomics P/S→
10X Genomics Stock
10X Genomics EBIT→
10X Genomics Stock
10X Genomics Dividend→
10X Genomics Stock
10X Genomics Directors Dealings→
10X Genomics Stock
10X Genomics Stocks→
10X Genomics Stock
10X Genomics Market capitalization→
10X Genomics Stock
10X Genomics Debt→
10X Genomics Stock
10X Genomics Liabilities→
10X Genomics Stock
10X Genomics Equity→
10X Genomics Stock
10X Genomics AAQS→
10X Genomics Stock
10X Genomics Employees→
10X Genomics Stock
10X Genomics ROE→
10X Genomics Stock
10X Genomics ROA→
10X Genomics Stock
10X Genomics ROCE→
10X Genomics Stock
10X Genomics News→
10X Genomics Stock
10X Genomics Analyst Price Targets→

Health Stocks

1933 IndustriesZyversa Therapeutics1CMZYUS Life Sciences21st NorthZymeworks2cureXZylox-Tonbridge Medical Technology Co3-D MatrixZydus Lifesciences3D Global BiotechZura BioAll Stocks A–Z →